Subscribe
shutterstock_1349460611_pavel_kapysh-1-1
Pavel Kapysh / Shutterstock.com
18 August 2022AmericasStaff Writer

Bausch Health unit prevails in patent dispute

New Jersey court dismissed a suit regarding an oral antibiotic | Prior art invalidated plaintiff’s four patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pharma unit could get green light to launch IBS generic
2 August 2022   Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
Americas
Bausch targets Israeli firm in skin treatment dispute
22 June 2023   Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.
Big Pharma
Bausch Ireland fends off challenge to its cancer patent
12 September 2023   Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Pharma unit could get green light to launch IBS generic
2 August 2022   Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
Americas
Bausch targets Israeli firm in skin treatment dispute
22 June 2023   Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.
Big Pharma
Bausch Ireland fends off challenge to its cancer patent
12 September 2023   Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.

More on this story

Americas
Pharma unit could get green light to launch IBS generic
2 August 2022   Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
Americas
Bausch targets Israeli firm in skin treatment dispute
22 June 2023   Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.
Big Pharma
Bausch Ireland fends off challenge to its cancer patent
12 September 2023   Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?